Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients

被引:8
|
作者
Zhang, Ziyin [1 ,2 ]
Zhang, Lu [1 ,2 ]
Jiang, Wangyan [1 ,2 ]
Du, Tingting [1 ,2 ]
Yuan, Gang [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Endocrinol, Wuhan 430030, Peoples R China
[2] Branch Natl Clin Res Ctr Metab Dis, Wuhan, Peoples R China
关键词
Non-obese non-alcoholic fatty liver disease; Cardio-metabolic risk; Type 2 diabetes mellitus; FATTY LIVER-DISEASE; PREVALENCE; ASSOCIATION;
D O I
10.1186/s12933-022-01648-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Non-obese non-alcoholic fatty liver disease (NAFLD) has been reported to share clinical outcomes with its obese counterpart in the general population. However, conflicting results have been observed regarding the cardio-metabolic risk profile of non-obese NAFLD as compared to obese NAFLD. Moreover, in the context of type 2 diabetes mellitus (T2DM), this issue has been even less addressed. We hence aimed to examine the association of NAFLD with the cardio-metabolic risk profile in patients with T2DM according to their obesity status. Methods A total of 2,708 patients with T2DM who were hospitalized between June 2018 and May 2021 were cross-sectionally assessed. Results The prevalence of NAFLD was 49.3%. NAFLD was found in 34.1% of non-obese patients and 66.0% of obese patients. Non-obese NAFLD patients had more and worse metabolic disorders than obese patients without NAFLD in both men and women. Comparable cardio-metabolic risk profiles were noted between non-obese and obese NAFLD subjects. The associations of worse cardio-metabolic risk profiles with NAFLD were overall stronger in non-obese than in obese subjects among women with T2DM, while more pronounced in obese than in non-obese subjects among men with T2DM. Conclusion In patients with T2DM, non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD. The associations of metabolic disorders with NAFLD were stronger in non-obese than in obese patients in women patients with T2DM.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD-Analysis of 10,865 Individuals
    Tan, Caitlyn
    Chan, Kai En
    Ng, Cheng Han
    Tseng, Michael
    Syn, Nicholas
    Tang, Ansel Shao Pin
    Chin, Yip Han
    Lim, Wen Hui
    Tan, Darren Jun Hao
    Chew, Nicholas
    Ong, Elden Yen Hng
    Koh, Teng Kiat
    Xiao, Jieling
    Chee, Douglas
    Valsan, Arun
    Siddiqui, Mohammad Shadab
    Huang, Daniel
    Noureddin, Mazen
    Wijarnpreecha, Karn
    Muthiah, Mark D.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [42] Association of Major Dietary Patterns with Cardio-metabolic Risk Factors in Type 2 Diabetic Patients
    Shadman, Zhaleh
    Akhoundan, Mahdieh
    Poorsoltan, Nooshin
    Larijani, Bagher
    Qorbani, Mostafa
    Hedayati, Mehdi
    Khoshniat Nikoo, Mohsen
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2016, 45 (11) : 1491 - 1501
  • [43] Soluble TNF receptors and albuminuria in non-obese Japanese type 2 diabetic patients
    Kawasaki, Y
    Taniguchi, A
    Fukushima, M
    Nakai, Y
    Kuroe, A
    Ohya, M
    Nagasaka, S
    Yamada, Y
    Inagaki, N
    Seino, Y
    HORMONE AND METABOLIC RESEARCH, 2005, 37 (10) : 617 - 621
  • [44] The effects of adiponectin and inflammatory cytokines on diabetic vascular complications in obese and non-obese patients with type 2 diabetes mellitus
    Hong, Seong Bin
    Lee, Jung Jin
    Kim, So Hun
    Suh, Young Ju
    Han, Ju Young
    Kim, Yong Seong
    Nam, Moonsuk
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 111 : 58 - 65
  • [45] Proteomic profiling of non-obese type 2 diabetic skeletal muscle
    Mullen, Edel
    Ohlendieck, Kay
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 25 (03) : 445 - 458
  • [46] HORMONAL-METABOLIC ASPECTS OF ATHEROGENIC DYSLIPIDAEMIAS IN NON-OBESE TYPE II DIABETIC PATIENTS WITH ATHEROSCLEROSIS
    Anestiadi, V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [47] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Christophe Bardin
    Estelle Nobecourt
    Etienne Larger
    François Chast
    Jean-Marc Treluyer
    Saik Urien
    European Journal of Clinical Pharmacology, 2012, 68 : 961 - 968
  • [48] Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.
    Cranmer, H
    Jones, NP
    Patwardhan, R
    DIABETOLOGIA, 1999, 42 : A228 - A228
  • [49] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Bardin, Christophe
    Nobecourt, Estelle
    Larger, Etienne
    Chast, Francois
    Treluyer, Jean-Marc
    Urien, Saik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 961 - 968
  • [50] Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients
    Ito, Takanori
    Nguyen, Vy H.
    Tanaka, Taku
    Park, Huiyul
    Yeh, Ming-Lun
    Kawanaka, Miwa
    Arai, Taeang
    Atsukawa, Masanori
    Yoon, Eileen L.
    Tsai, Pei -Chien
    Toyoda, Hidenori
    Huang, Jee-Fu
    Henry, Linda
    Jun, Dae Won
    Yu, Ming -Lung
    Ishigami, Masatoshi
    Nguyen, Mindie H.
    Cheung, Ramsey C.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (04) : 1013 - +